N/A N=32 Magnetic Resonance Imaging in Subjects With Gouty Tophi
Hyperuricemia · Gout
Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=13 Validation Study of Physical Measurement of Tophi
Gout
Primary: Average Percent Difference in Area Between Visits — 29 mm²
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 3 N=324 Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Tophaceous Gout
Primary: Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6 — 0.566; 0.761; 0.468 Proportion of Subjects — p=0.1298
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 3 N=153 A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
Chronic Gout
Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…
Phase 3 N=112 A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
Chronic Gout
Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Early Phase 1 N=8 Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Calcium Pyrophosphate Deposition Disease
Primary: ATP Levels in Synovial Fluid — 4.4; 31.4 nanomoles/ml
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 2 N=99 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Hyperuricosuria · Kidney Stones
Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001
Phase 4 N=196 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
Gout
Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001
Phase 3 N=19 Phentermine/Topiramate for Uric Acid Stones
Obesity · Uric Acid Stones · Type 2 Diabetes Mellitus in Obese
Primary: Kidney Stone Size (mm^3) Determined by Non-contrast CAT Scan — 6540; 4650; 3120; 5041 mm^3
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
Phase 2 N=96 Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Renal Impairment
Primary: Change From Baseline to Month 12 in Serum Creatinine — 2.52; 2.10; 2.22; 0.19 mg/dL — p=0.459
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
Phase 4 N=152 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001
Phase 2 N=204 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Gout and Hyperuricemia
Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001
Phase 2 N=200 Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Acute Gout
Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
Phase 4 N=15 Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6 — 78.6 percentage of participants
Phase 2 N=153 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001
Phase 2 N=64 RDEA3170 and Febuxostat Combination Study in Gout Subjects
Gout
Primary: Serum Urate Maximum Percentage (%) Change (Emax, CB) — -43.5; -55.6; -70.4; -79.1 Percentage (%) — p=<0.0001